Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Prothrombin Complex Concentrate (PCC) Market: By Product; By Application: Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency; By End Use; Hospitals, Ambulatory Surgical Centres; Regional Analysis; Historical Market and Forecast (2017-2027); Competitive Landscape; Industry Events and Developments
Global Prothrombin Complex Concentrate (PCC) Market Outlook
The global prothrombin complex concentrate (PCC) market is expected to grow at a CAGR of about 9% in the forecast period of 2022-2027.
-market.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America and Europe to Substantially Boost the Prothrombin Complex Concentrate (PCC) Industry
North America and Europe will be among of the leading regions for prothrombin complex concentrate (PCC) owing to its clinical advantage over fresh frozen plasma. With the advent of Covid-19, there has been an increase in the demand for the PCC. It is because of the noticeable success of plasma-based therapies in the patients. The Asia Pacific region is also expected to rise rapidly with the adoption of Kcentra which was approved by the United States Food and Drug Administration (FDA). The market is also expected to be developed in Latin America and Middle East and Africa with the increased spending on healthcare and improvement of distribution mechanisms.
Prothrombin Complex Concentrate (PCC): Industry Definition and Segmentation
Prothrombin complex concentrate (PCC) is produced from human plasma and used as a medication comprising blood clotting. It is utilised in the treatment of hemophilia to prevent bleeding. Vitamin K antagonist treatment also accompanies the usage of PCC when acute bleeding occurs. This is listed as one of the safest and most effective medicine in World Health Organisation’s list of essential medicines required in health system.
-market-by-end-use.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
PCC can be divided on the basis of product into:
- 3-Factor PCC
- 4-Factor PCC
- Others
On the basis of application, PCC can be divided into:
- Acquired Coagulation Factor Deficiency
- Congenital Coagulation Factor Deficiency
- Others
PCC finds its end use in the following:
- Hospitals
- Ambulatory Surgical Centres
- Others
The regional markets for PCC can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
-market-by-region.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Prothrombin Complex Concentrate (PCC) Market to Rise with its Advantage over Fresh Frozen Plasma
PCC is expected to have a significant rise because of its clinical advantage against fresh frozen plasma (FPP). PCC needs less volume and infusion time when compared to FFP and is more effective. PCC also does not require blood matching and thawing like FFP. The widespread use of Vitamin K antagonist like warfarin is also expected to drive robust industry growth for PCC. According to FDA, the adult patients undergoing Vitamin K antagonist treatment can have acquired coagulation factor deficiency. In case of acute bleeding, the urgent reversal for such can be done with the indication of PCC, Kcentra. Hemophilic patients are expected to increase in number over upcoming years. Their treatment requires PCC which will further boost the demand. The recent government policies have also worked in the favour for PCC with the relaxation in its usage approval. Government funding has also promoted the use of PCC for bleeding control. COVID-19 has seen rise in plasma related therapies which has rapidly increased PCC demand. Plasma collection centres have been set up by key players to stock up blood demand in PCC.
Key Industry Players in the Global Prothrombin Complex Concentrate (PCC) Market
The report gives a detailed analysis of the following key players in the global prothrombin complex concentrate (PCC) market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- CSL Behring GmbH
- Octapharma AG
- Kedrion S.p.A
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product, Application, End Use, Region |
| Breakup by Product | 3-Factor PCC, 4-Factor PCC, Others |
| Breakup by Application | Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, Others |
| Breakup by End Use | Hospitals, Ambulatory Surgical Centres, Others |
| Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | CSL Behring GmbH, Octapharma AG, Kedrion S.p.A, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Prothrombin Complex Concentrate (PCC) Market Analysis
8.1 Key Industry Highlights
8.2 Global Prothrombin Complex Concentrate (PCC) Historical Market (2017-2021)
8.3 Global Prothrombin Complex Concentrate (PCC) Market Forecast (2022-2027)
8.4 Global Prothrombin Complex Concentrate (PCC) Market by Product
8.4.1 3-Factor PCC
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 4-Factor PCC
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Others
8.5 Global Prothrombin Complex Concentrate (PCC) Market by Application
8.5.1 Acquired Coagulation Factor Deficiency
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Congenital Coagulation Factor Deficiency
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Others
8.6 Global Prothrombin Complex Concentrate (PCC) Market by End Use
8.6.1 Hospitals
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Ambulatory Surgical Centres
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Others
8.7 Global Prothrombin Complex Concentrate (PCC) Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 CSL Behring GmbH
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Octapharma AG
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Kedrion S.p.A
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Others
13 Industry Events and Developments
List of Figures and Tables
1. Global Prothrombin Complex Concentrate (PCC) Market: Key Industry Highlights, 2016 and 2026
2. Global Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Product (USD Billion), 2017-2021
3. Global Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Product (USD Billion), 2022-2027
4. Global Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Application (USD Billion), 2017-2021
5. Global Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Application (USD Billion), 2022-2027
6. Global Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by End Use (USD Billion), 2017-2021
7. Global Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by End Use (USD Billion), 2022-2027
8. Global Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Region (USD Billion), 2017-2021
9. Global Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Region (USD Billion), 2022-2027
10. North America Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2017-2021
11. North America Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Europe Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Europe Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Asia Pacific Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Asia Pacific Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Latin America Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Latin America Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Middle East and Africa Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Middle East and Africa Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Global Prothrombin Complex Concentrate (PCC) Market Structure
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The India biosimilar market size reached a value of almost USD 633 million in the year 2020. The market is further expected to grow at a CAGR of 11% between 2021 and 2026.
The global human insulin market attained USD 36 billion in 2020. The market is expected to grow at a CAGR of 4.7% in the forecast period of 2022-2027 to attain USD 48 billion by 2026.
The global biosimilar market size reached a value of almost USD 16.6 billion in the year 2020. The biosimilar market is further expected to grow at a CAGR of 18.1% between 2021 and 2026 to reach a val...
The Europe biosimilar market attained a value of USD 2,945 million in the year 2020 driven by the growing geriatric population in the region. Aided by the low cost of the product and the expected expi...
The global tumour necrosis factor inhibitor drugs market attained a value of USD 40.3 billion in 2020, driven by the increased incidences of different inflammatory diseases. Aided by the development o...
NEWSLETTER